[ Search ] [ PDF text ] [ Legislation ]
[ Home ] [ Back ] [ Bottom ]
92_HB4894 LRB9213770SMdv 1 AN ACT in relation to taxation. 2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly: 4 Section 5. The Illinois Income Tax Act is amended by 5 adding Section 213 as follows: 6 (35 ILCS 5/213 new) 7 Sec. 213. Pharmaceutical production tax credit. 8 (a) For taxable years ending on or after September 12, 9 2001, a taxpayer is entitled to a credit against the tax 10 imposed under subsections (a) and (b) of Section 201 for the 11 taxpayer's pharmaceutical production expense incurred and 12 paid during the taxable year and after September 11, 2001 in 13 an amount equal to the lesser of the taxpayer's income tax 14 liability under subsections (a) and (b) of Section 201 for 15 the taxable year or the amount determined in subdivision 16 (a)(3) by completing the following steps: 17 (1) Add the pharmaceutical production expenses 18 incurred by the taxpayer in the taxable year. 19 (2) Multiply the result determined in subdivision 20 (a)(1) by one-tenth. 21 (3) Add the product determined in subdivision 22 (a)(2) to the credit carryforward, if any, to which the 23 taxpayer is entitled for the taxable year under 24 subsection (b). 25 (b) If the amount determined under subsection (a) for a 26 taxpayer in a taxable year exceeds the taxpayer's income tax 27 liability under subsections (a) and (b) of Section 201 for 28 the taxable year, the taxpayer may carry forward the excess 29 to the immediately following taxable year. A taxpayer is not 30 entitled to a carryback or refund of any unused credit. 31 (c) To receive the credit authorized under this Section, -2- LRB9213770SMdv 1 a taxpayer must submit to the Department all information that 2 the Department determines is necessary for the calculation of 3 the credit and for the determination of whether an expense 4 was a qualified expense. 5 (d) If a pass through entity is entitled to a credit 6 under this Section but does not have income tax liability 7 against which the credit may be applied, a shareholder, 8 partner, or member of the pass through entity is entitled to 9 a tax credit equal to: 10 (1) the tax credit determined for the pass through 11 entity for the taxable year; multiplied by 12 (2) the percentage of the pass through entity's 13 distributed income to which the shareholder, partner, or 14 member is entitled. 15 (e) As used in this Section: 16 "Antibiotic drug" means any drug intended for use by man 17 containing any quantity of any chemical substance that is 18 produced by a microorganism and which has the capacity to 19 inhibit or destroy microorganisms in dilute solution 20 (including the chemically synthesized equivalent of any such 21 substance). 22 "Base level" means a taxpayer's average daily 23 pharmaceutical production for the 365-day period ending 24 September 11, 2001. 25 "Pharmaceutical production" means a taxpayer's production 26 of antibiotic drugs and vaccines that are used to treat 27 bioterrorism agents, including anthrax and smallpox. 28 "Pharmaceutical production expense" means an expense 29 incurred by a taxpayer to increase the taxpayer's 30 pharmaceutical production above the taxpayer's base level. 31 "Taxpayer" means an individual, corporation, trust or 32 estate, or a partnership. 33 (f) This Section is exempt from the provisions of 34 Section 250.
[ Top ]